Boothbay Fund Management’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Other funds holding RLMD
JHC
Boothbay Fund Management's RLMD Position: Q3 2026 in Review
Boothbay Fund Management reduced its Relmada Therapeutics (RLMD) stake by 34% in Q3 2026, selling an estimated $944K and leaving 372,300 shares worth $1.4M. The position accounts for 0.02% of the portfolio, ranked #776.
Boothbay Fund Management first reported a position in RLMD in Q1 2021 and has held it in 10 quarters since. The position peaked at $5.07M in Q1 2026. 135 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.
- Boothbay Fund Management held 372,300 shares of Relmada Therapeutics worth $1.4M as of Q3 2026.
- Boothbay Fund Management sold 192,459 Relmada Therapeutics shares in Q3 2026, an estimated $944K.
- Relmada Therapeutics made up 0.02% of Boothbay Fund Management's portfolio in Q3 2026, its #776 holding.
- Boothbay Fund Management first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 10 quarters since.
- Boothbay Fund Management's Relmada Therapeutics position peaked at $5.07M in Q1 2026.
- 135 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.
Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.